Slight Headache; This is a spontaneous report received from a Consumer or other non HCP from License Party. A 72-year-old female patient (not pregnant) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPILUMAB), since 01Aug2024 (ongoing)) at 300 mg weekly, subcutaneous for asthma. The patient’s relevant medical history was not reported. Concomitant medication(s) included: CARVEDILOL; BUDESONIDE; BREO ELLIPTA; VALACYCLOVIR [VALACICLOVIR HYDROCHLORIDE]; SPIRIVA; MAGNESIUM OXIDE; VITAMIN D [COLECALCIFEROL]; CALCIUM CARBONATE. The following information was reported: HEADACHE (non-serious), outcome “unknown”, described as “Slight Headache”. The action taken for dupilumab was dosage not changed. Additional information: It was reported that, “the patient asking if okay to inject Dupixent the day after her Covid vaccine. I advised no issue. The patient has a slight headache after getting vaccine. Batch/lot number is not provided, and it cannot be obtained.